Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Guanylate Cyclase

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_243

Synonyms

Historical Background

The concept of second messenger molecules in hormone signal transduction was developed in the 1950s by Earl W. Sutherland describing the cyclic nucleotide adenosine 3′, 5′-cyclic monophosphate (cAMP) as an intracellular messenger molecule. The main features of this concept are the binding of a hormone to the extracellular site of a transmembrane receptor protein which triggers an intracellular response mediated by a second messenger molecule (e.g., cAMP). Shortly after cAMP was discovered as second messenger in hormone signaling, another cyclic nucleotide abbreviated cGMP (guanosine 3′, 5′-cyclic monophosphate) was first detected in rat urine (Ashman et al. 1963) and soon after was found in a variety of other tissues and biological samples. Every second messenger system requires the presence of synthesizing and degrading enzymes. For cyclic purine monophosphates these are adenylate and guanylate cyclases and specific forms of phosphodiesterases, respectively. Guanylate cyclases (GCs) catalyze the conversion of GTP to cGMP according to the reaction scheme: GTP → cGMP + pyrophosphate (PP i). The development of suitable and effective enzymatic assays led in 1969 to several publications that report on the determination of GC activity. Consequent studies then revealed that GC activities cofractionated with soluble and particulate membrane fractions, but it was not before the mid to late 1980s that soluble and membrane-bound GCs were purified from mammalian sources to apparent homogeneity. Subsequent cloning studies in the late 1980s and early 1990s using tissue-specific cDNA libraries resulted in deduced primary structures of soluble and particulate GC isoforms. Studies on mammalian GCs were inspired by work on sea urchin sperm that is a rich source of a particulate GC and that is activated by certain peptides. In mammalians it was known already from reports in the 1970s that neuromediators like acetylcholine could regulate the cGMP level in perfused heart tissue, but the physiological pathways linking these steps remained unclear until the 1980s. Then several discoveries showed that cGMP is the second messenger of important physiological responses including smooth muscle relaxation, intestinal fluid and electrolyte homeostasis, and sensory physiology, in particular phototransduction. Several physiologically relevant molecules that regulate and/or trigger activation of GCs were identified and characterized in the last three decades. The most important so far are nitric oxide for the soluble isoforms and natriuretic peptides, paracrine intestinal hormones, and changes in cytoplasmic Ca2+ levels in combination with Ca2+-sensor proteins for the different particulate isoforms. The identification of these regulatory molecules paved the way for integrating GC isoforms in signaling pathways or led to formulation of new signaling concepts (for historical aspects see Beavo and Brunton 2002; Kots et al. 2009; Sharma 2010; Kuhn 2016).

Guanylate Cyclase Forms

Seven different forms of a membrane GC and two α- and β-subunits of the soluble form are expressed in a wide range of mammalian tissues (see under “Tissue Distribution”). They are classified on the basis of their amino acid sequences and according to their ligands or intracellular regulators (for each GC forms synonymous names are found in the literature and are given below):

Membrane-bound GCs

Soluble GCs

GC-A/ANF-RGC//NPR-A

sGC α1

GC-B/CNP-RGC/NPR-B

sGC α2

GC-C/STa-RGC/Guanylin receptor

sGC β1

GC-D/ONE-GC

sGC β2

GC-E/ROS-GC1/retGC-1

 

GC-F/ROS-GC2/retGC-2

 

GC-G

 

In addition GCs are also found in nonmammalian vertebrates like teleost fishes, in insects, nematodes, unicellular eukaryotic organisms, and bacteria (Baker and Kelly 2004; Ortiz et al. 2006; Rätscho et al. 2010). Some of these organisms express a larger variety of GCs than mammalians and are at least partially homologous to the GC forms found in mammalians.

Protein Structure and Topography

Membrane-bound and soluble GCs share some common structural features but also differ in those protein domains that are important for their regulation by extracellular or intracellular factors (Lucas et al. 2000; Tamura et al. 2001). Figure 1 shows the main topographic features of these GC forms. Membrane (particulate) GCs are homodimers, whereas soluble GCs function as heterodimers. Both subtypes contain a cyclase catalytic domain with a high amino acid sequence homology among all GCs and significant homology to adenylate cyclases. Invariant amino acids in the catalytic domain define the substrate specificity (binding of GTP or ATP). The catalytic domain of the membrane-bound isoforms is extended by a C-terminal tail of varying length, which is not present in soluble GCs. Both subtypes also contain a dimerization domain that is N-terminal to the catalytic domain. This domain has the structural features of an amphipathic α-helix allowing forming of a two-stranded α-helical coiled coil. The third large domain of the cytoplasmic part of membrane-bound GCs is the kinase homology domain that consists of approximately 250 amino acids. It shows partial amino acid sequence homology to protein tyrosine kinase receptors and harbors an ATP-binding motif that is identical or similar to the ATP-binding motif of the catalytic subdomains of protein kinases (the sequence GxGxxG that is rich in glycine is conserved in some GCs, but not in all). Particulate GCs are anchored in the membrane by a single transmembrane domain that has an amino acid sequence typical for an α-helical transmembrane region found in other membrane receptor proteins. While it is clear that this segment is important for membrane localization it is unresolved whether it also mediates transmembrane signaling. The different particulate subtypes might differ in this aspect. A short segment of amino acids called the juxtamembrane domain is sandwiched between the kinase homology and the transmembrane domain. Depending on the subtype of particulate GC this region consists of 25–100 amino acids. The more extended forms of the juxtamembrane region are found in the sensory GCs.
Guanylate Cyclase, Fig. 1

Domain topography of membrane and soluble GCs

Instead of a kinase homology domain soluble GCs contain a heme-binding domain that is N-terminally located from the amphipathic dimerization domain (Fig. 1). The two heme-binding domains of one soluble GC heterodimer coordinate a heme prosthetic group (a porphyrin ring structure with a central ferrous ion (Fe 2+)) that is required for the enzyme to become activated by nitric oxide (see below).

The least homology among all membrane-bound GCs is found in the extracellular domain. This large domain consists of approximately 500 amino acids and harbors the ligand-binding region, in which the ligand can be either a hormone or an odorant molecule depending on the GC subtype. Sensory GCs that are expressed in the photoreceptor cells of the vertebrate retina are an exception of this rule. No external ligand is known for the extracellular domain of these GCs, and in the case of GCs expressed in rod photoreceptor cells the corresponding extracellular domain is located in the disk lumen.

Tissue Distribution

The natriuretic peptide receptor GCs GC-A and GC-B show the most diverse tissue distribution (Lucas et al. 2000; Tamura et al. 2001). GC-A is expressed in adrenal gland, pituitary gland, adipose tissue, cerebellum, aorta, heart, kidney, liver, spleen, testis, colon, brain stem, retina, cochlea, ovary, thymus, and others. Expression of GC-B largely overlaps with that of GC-A, but a more specific expression pattern is found for GC-C, the intestinal receptor for guanylin and uroguanylin. This GC is mainly present in the colon and intestine but is also found in the kidney, testis, and liver. A similar expression profile (lung, kidney, skeletal muscle, and intestine) is found for GC-G. Different from these receptor-type GCs are the sensory GCs that display a very restricted expression profile. For example, the odorant receptor GC-D is found in a subset of sensory neurons of the olfactory neuroepithelium (Sharma and Duda 2010; Zufall and Munger 2010), and the retina-specific GC-E and GC-F (ROS-GC1 and ROS-GC2) are predominantly expressed in photoreceptor cells of the vertebrate retina (Koch et al. 2010). In addition, GC-E is also found in the pineal gland.

Soluble GC forms are widely distributed and are mainly present in lung, heart, liver, kidney, cerebellum, skeletal muscle, and retina, whereby expression of the β2 isoform seems to be more restricted.

Mode of Activation and Regulation

Natriuretic peptides (NP) act on two types of membrane-bound GCs, GC-A and GC-B, and are a family of three factors (Potter et al. 2009; Martel et al. 2010). These factors are named ANP, BNP, and CNP. The active forms of these hormones/paracrine factors are between 22 and 53 amino acids long and circulate in the blood stream after posttranslational proteolytic cleavage from longer forms. ANP and BNP are secreted from cardiac myocytes and act on GC-A; CNP is secreted in the brain, chondrocytes, and epithelial cells and acts on GC-B. All peptides bind to the extracellular domain of the GC subgroup of natriuretic peptide receptors and thereby increase the guanylate cyclase activity of the receptor. The basal state of GC-A and GC-B exhibits very low GC activity, is highly phosphorylated (at serine and threonine residues), and forms homodimers. Binding of the peptide induces a conformational change enabling ATP to bind to the intracellular KHD, which is an allosteric control step for transducing the hormone signal to the cyclase catalytic domain (Fig. 2). Prolonged exposure of natriuretic peptides to the receptors leads to dephosphorylation and desensitization. Another class of peptides, guanylin and uroguanylin, are the endogenous activator of the intestinal GC-C controlling fluid and ion transport, and also renewal of epithelial cells. In addition, GC-C is specifically activated by bacterial heat-stable enterotoxins (STa) that cause severe secretory diarrhea via a cGMP-mediated signaling pathway (Lin et al. 2009; Kuhn 2016). The odorant receptor GC-D is also activated by uroguanylin and guanylin as well as by natural urine stimuli and bicarbonate leading to an increase in cGMP synthesis (Zufall and Munger 2010). A further control mode is the regulation by so-called neuronal Ca2+-sensor (NCS) proteins that regulate the GC activity from the cytoplasmic part of the receptor (Fig. 2). GC-D is related to the other sensory GCs (GC-E and GC-F) that mainly operate in the outer segments of vertebrate photoreceptors and are regulated by intracellular NCS proteins named guanylate cyclase-activating proteins (GCAPs). Light triggers the decrease of the intracellular messenger cGMP and with a short delay the decrease of the cytoplasmic Ca2+concentration as well. Changing concentrations of Ca2+ are sensed by GCAPs that form a complex with the target GC and undergo a Ca2+-induced conformational change. This in turn leads to an increase of catalytic activity at the cyclase catalytic domain (Fig. 2). No ligands are known for retina-specific GCs, and it is unknown whether binding of a ligand to the extracellular (intradiskal) site is at all necessary. Binding of ATP to the intracellular KHD is known to enhance the GC activity (Koch et al. 2010).
Guanylate Cyclase, Fig. 2

Modes of GC activation and regulation. Natriuretic peptides (NP) bind and thereby activate peptide receptor GCs that are phosphorylated (-P) in the basal state. The hormone signal is transferred to the catalytic domain under control of ATP. Sensory GCs are under control of Ca2+-sensor proteins (NCS, GCAP) at the intracellular site. GC-D in olfactory sensory neurons is also activated by guanylin (Gua) and uroguanylin at the extracellular site, whereas no ligand appears necessary for the activation of photoreceptor GCs. GCAPs sense changes in intracellular Ca2+ and in turn activate photoreceptor GCs at low Ca2+concentrations. NO and CO can pass the cell membrane and stimulate soluble GCs

Soluble GCs are activated by a fundamentally different mechanism. Gaseous molecules like NO and CO bind to the heme prosthetic group that is held between the two subunits forming the heterodimeric GC (Fig. 2). Binding of NO to the Fe2+ in the porphyrin ring of the heme group triggers the breakage of histidine coordinating bond and leads in consequence to a conformational change. By this mechanism the GC activity can be stimulated by about 5000-fold (Garthwaite 2010).

Signaling Pathways and Physiological Responses Involving Guanylate Cyclases

The different GC forms are involved in complex physiological responses mirrored in the large variety of tissue. For example, the natriuretic peptide receptor GC-A is involved in regulation of blood pressure as this was demonstrated by transgenic mice lacking the receptor or the activating peptide ANP. Key steps in blood pressure regulation are vascular smooth muscle relaxation and contraction, which are under control of intracellular Ca2+spikes. In the kidney, ANP controls the fluid and electrolyte secretion by an increase of the glomerular filtration rate. These responses are triggered by an elevation of the intracellular cGMP level (Lucas et al. 2000; Tamura et al. 2001; Martel et al. 2010). Three main intracellular targets of cGMP are known so far including protein kinase G (PKG), a cAMP-hydrolyzing phosphodiesterase (PDE), and cyclic nucleotide-gated (CNG) channels. In particular PKG and PDE are involved in blood pressure regulation. PKG is known to activate or inhibit Ca2+-transport systems in vascular smooth muscle cells by phosphorylation. These include Ca2+-activated potassium channels, Ca2+ATPases in the plasma membrane and in the sarcoplasmic reticulum, voltage-dependent Ca2+ channels, and the inositol 1,4,5-triphosphate receptor. In addition PKG controls enzymes like myosin light chain phosphatase (Fig. 3).
Guanylate Cyclase, Fig. 3

Comparison of signaling pathways involving membrane-bound GCs and synthesis of cGMP. Targets of cGMP are PKG, cAMP-specific PDE, and CNG-channels. PKG can phosphorylate and thereby regulate many targets including Ca2+-transport systems, Ca2+-activated K+-channels, and myosin light chain phosphatase (MLCP). Inhibition of PDE by cGMP that is synthesized by GC-C in intestine can lead to an increase of cAMP and activation of PKA, in particular during toxin (STa)-induced activation of GC-C. Both kinases (PKG and PKA) phosphorylate the CFTR and thereby increase its chloride permeability. CNG-channels in photoreceptor cells bind directly to cGMP leading to an opening of the channel and an influx of Na+ and Ca2+ into the cell

Additional effects of cGMP that are mediated via natriuretic peptide signaling are cardiac hypertrophy and fat metabolism. The factor CNP that acts on GC-B stimulates bone growth and is involved in vascular remodeling.

The paracrine hormones guanylin and uroguanylin regulate the fluid and electrolyte homeostasis in intestinal epithelial cells by binding to the extracellular site of GC-C. A similar ligand-receptor interaction is observed with bacterial enterotoxins leading also to an increase of intracellular cGMP. The latter is a major cause of secretory diarrheal disease. Elevated levels of cGMP activate PKG type II, but can also inhibit a cAMP-specific PDE leading to an increase in cAMP levels and in consequence to an activation of protein kinase A (PKA). PKGII and PKA then phosphorylate and thereby activate the cystic fibrosis transmembrane regulator (CFTR) a chloride-ion channel in the intestinal brush border membrane (Fig. 3).

Sensory GCs are predominantly expressed in sensory cell types and are part of signaling pathways that have CNG-channels instead of PKGs as main downstream targets of cGMP. Among them GC-D is a receptor GC that can be activated by the ligand peptides guanylin and uroguanylin (see above). GC-D is present in a subpopulation of olfactory sensory neurons and not part of the predominant cAMP-signaling pathway in most olfactory sensory neurons. Intracellular signaling of GC-D is linked to Ca2+-signaling pathways as well, since Ca2+-binding proteins of the NCS protein subfamily were shown to regulate GC activity by binding to intracellular regions of GC-D. These NCS proteins are GCAP1, neurocalcin-δ, frequenin, and  hippocalcin. The biological role of GC-D has been discussed in the context of chemosensory detection of the metabolic status (Sharma and Duda 2010; Zufall and Munger 2010).

Vision in vertebrate photoreceptor cells involves membrane-bound GCs that are regulated by intracellular Ca2+-binding proteins named GCAPs. No extracellular ligands are known so far. Mammalian rod and cone cells express GC-E and GC-F. They synthesize the intracellular messenger of visual excitation, cGMP, thereby keeping the CNG-channels open to allow influx of Na+ and Ca2+ from the extracellular medium in the dark adapted state of the cell. GCAPs are an important regulatory part of an intracellular feedback loop, since they activate photoreceptor GCs at low Ca2+concentration and inhibit them at higher Ca2+concentration leading to resynthesis of cGMP after illumination, when the cytoplasmic Ca2+concentration has dropped (Fig. 3). Photoreceptor GCs are key components of signal transduction in rod and cone cells by controlling the second messenger level. Thereby they are important for the cell’s recovery to the dark state after illumination and its adaptational properties (Koch et al. 2010).

Soluble GCs are the target of the versatile messenger molecule NO that is synthesized by nitric oxide synthase isoforms. NO, for example, is mediating smooth muscle relaxation and is involved in the central and peripheral nervous system and in the immune response of macrophages. NO can act on other targets than soluble GCs, but increase of cGMP production by NO leads in general to activation of PKG and subsequent phosphorylation of PKG targets.

Summary

The second messenger cGMP and its synthesizing enzymes (membrane and soluble GCs) have become essential parts of different signaling pathways that mediate important physiological functions. These include, for example, blood pressure regulation, kidney and smooth muscle function, olfaction, and vision. Components of the corresponding signaling pathways have been characterized at the molecular level, and the physiological impact of GCs has been investigated by a combination of biochemical, genetic, and physiological studies. For these systems a deeper mechanistic understanding at the structural level has also partially been achieved. Elucidating the structure-function relationships of GCs and their regulatory components will also guide future directions of pharmaceutical and therapeutical inventions, since several diseases correlate with dysfunctions of GC-signaling systems. These include, for example, hypertension, different forms of retinal degeneration, and colorectal cancer. Another challenge is to dissect other signaling pathways, in which cGMP has been implicated, but information on a participating GC in these pathways is missing. Examples are other sensory cell systems (e.g., sensing of tastants, heat, and pain) or the Wnt-frizzled signaling pathway in early embryonic development (Wang and Malbon 2004). Finally, some nonmammalian organisms express a larger variety of GC forms than mammalians. It will be a promising task to investigate the properties and the operation principles of these GC forms in an environmental and evolutionary context.

References

  1. Ashman DF, Lipton R, Melicow MM, Price TD. Isolation of adenosine 3′,5′-monophosphate and guanosine3′,5′-monophosphate from rat urine. Biochem Biophys Res Commun. 1963;11:330–4.PubMedCrossRefGoogle Scholar
  2. Baker DA, Kelly JM. Structure, function and evolution of microbial adenylyl and guanylyl cyclases. Mol Microbiol. 2004;52:1229–42.PubMedCrossRefGoogle Scholar
  3. Beavo JA, Brunton LL. Cyclic nucleotide research – still expanding after half a century. Nat Rev Mol Cell Biol. 2002;3:710–8.PubMedCrossRefGoogle Scholar
  4. Garthwaite J. New insight into the functioning of nitric oxide-receptive guanylyl cyclase: physiological and pharmacologicalimplications. Mol Cell Biochem. 2010;334:221–32.PubMedCrossRefGoogle Scholar
  5. Koch KW, Duda T, Sharma RK. Ca 2+-modulated vision-linked ROS-GC guanylate cyclase transduction machinery. Mol Cell Biochem. 2010;334:105–15.PubMedCrossRefGoogle Scholar
  6. Kots AY, Martin E, Sharina IG, Murad F. A short history of cGMP, guanylyl cyclases, and cGMP-dependent protein kinases. In: Schmidt HHHW et al., editors. cGMP: generators, effectors and therapeutic implications, handbook of experimental pharmacology, vol. 191. Berlin/Heidelberg: Springer; 2009. p. 1–14.CrossRefGoogle Scholar
  7. Kuhn M. Molecular physiology of membrane guanylyl cyclase receptors. Physiol Rev. 2016;96:751–804.PubMedCrossRefGoogle Scholar
  8. Lin JE, Li P, Pitari GM, Schulz S, Waldman SA. Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target. Future Oncol. 2009;5:509–22.PubMedCrossRefPubMedCentralGoogle Scholar
  9. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepnik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52:375–413.PubMedPubMedCentralGoogle Scholar
  10. Martel G, Hamet P, Trembly J. Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome. Mol Cell Biochem. 2010;334:53–65.PubMedCrossRefGoogle Scholar
  11. Ortiz CO, Etchberger JF, Posy SL, Frokjaer-Jensen C, Lockery S, Honig B, Hobert O. Searching for neuronal left/right asymmetry: genomewide analysis of nematode receptor-type guanylyl cyclases. Genetics. 2006;173:131–49.PubMedCrossRefPubMedCentralGoogle Scholar
  12. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiological functions and therapeutic applications. In: Schmidt HHHW et al., editors. cGMP: generators, effectors and therapeutic implications, handbook of experimental pharmacology, vol. 191. Berlin/Heidelberg: Springer; 2009. p. 341–66.CrossRefGoogle Scholar
  13. Rätscho N, Scholten A, Koch KW. Diversity of guanylate cyclases in teleost fishes. Mol Cell Biochem. 2010;334:207–14.PubMedCrossRefGoogle Scholar
  14. Sharma RK. Membrane guanylate cyclase is a beautiful signal transduction machine: overview. Mol Cell Biochem. 2010;334:3–36.PubMedCrossRefGoogle Scholar
  15. Sharma RK, Duda T. Odorant-linked ROS-GC subfamily membrane guanylate cyclase transduction system. Mol Cell Biochem. 2010;334:181–9.PubMedCrossRefGoogle Scholar
  16. Tamura N, Chrisman TD, Garbers DL. The regulation and physiological roles of the guanylyl cyclase receptors. Endocrine J. 2001;48:611–34.CrossRefGoogle Scholar
  17. Wang HY, Malbon CC. Wnt-frizzled signaling to G-protein-coupled effectors. Cell Mol Life Sci. 2004;61:69–75.PubMedCrossRefGoogle Scholar
  18. Zufall F, Munger SD. Receptor guanylyl cyclases in mammalian olfactory function. Mol Cell Biochem. 2010;334:191–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of NeurosciencesUniversity of OldenburgOldenburgGermany